RNA-derived medicines: a review of the research trends and developments

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

RNA-derived medicines: a review of the research trends and developments

Sponsored by

Logo 22.07.22.png
Coronavirus RNA strand. Medical illustration. 3D rendering

CAS considers how the emerging field of RNA therapeutics highlights trends in targets, chemical modifications, and new delivery systems that increase stability of RNA

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine. RNA technology provides an innovative approach to developing drugs against difficult or challenging therapeutic targets, holding potential across many diseases ranging from the largest global health challenges to extremely rare diseases.

However, RNA medicine has faced many challenges: RNA molecules are relatively unstable and transient, the limited translation into cellular protein expression can hinder efficacy, and foreign RNA molecules often trigger immunogenicity. Furthermore, the delivery of RNA molecules can be a challenge due to their relatively large size and high electric charge.

Some of these practical problems can be mitigated by chemically modifying the RNA, providing the opportunity to develop therapeutics that are more stable, effective, and tolerable for patients. The recent success of mRNA vaccines against COVID-19 and the approval of new RNA-based drugs has provided new momentum to the field, building on the key milestones and achievements of the last 60 years. Advances in our understanding of RNA structure and function, combined with a robust production pipeline, have substantially increased the capacity to develop clinically effective RNA-related applications.

In this white paper, CAS used data from the CAS Content CollectionTM—the largest human-curated collection of published scientific knowledge—to review publication trends in RNA research, the application of RNA in medicine and the use of chemical modifications and nanotechnology to improve the delivery and efficacy of RNA pharmaceuticals. The white paper focuses on chemical modifications to the nucleic acid base, backbone, and sugar molecules to increase RNA stability, along with the new delivery systems that are critical to the success of RNA medicine.

Click here to access CAS’s white paper – “RNA-derived medicines: a review of the research trends and developments”

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article